<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="104104">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01782261</url>
  </required_header>
  <id_info>
    <org_study_id>ADPP004</org_study_id>
    <secondary_id>2011-006300-12</secondary_id>
    <nct_id>NCT01782261</nct_id>
  </id_info>
  <brief_title>Incretin Effect on the Immunological Phenotype</brief_title>
  <official_title>Pilot Study on Incretin Effect on the Immunological Phenotype in Healthy Subjects and in Type 1 Diabetic Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Graz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Graz</source>
  <oversight_info>
    <authority>Austria: Federal Office for Safety in Health Care</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assessment of the effect of incretin based therapies (Liraglutide and Saxagliptin) on immune
      cells in healthy subjects and patients with type 1 diabetes
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Assessment of immunological effects of Saxagliptin and Liraglutide on immune cells of the
      peripheral blood.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">September 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Increase of regulatory FOXP3+ T cells</measure>
    <time_frame>4 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>the effects of incretin based therapy on regulatory FOXP3+ T cells will be measured at baseline and after 4 weeks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunophenotyping</measure>
    <time_frame>4 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>The effect of incretin based therapy on circulating immune cells and cytokine secretion at baseline and after 4 weeks</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Type 1 Diabetes</condition>
  <arm_group>
    <arm_group_label>Liraglutide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Liraglutide subcutaneous injection every day. first week 0.6mg, week 2-4 1.2mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saxagliptin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Saxagliptin 5mg tablet by mouth every day for 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liraglutide</intervention_name>
    <description>once daily subcutaneous injection</description>
    <arm_group_label>Liraglutide</arm_group_label>
    <other_name>Victoza</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saxagliptin</intervention_name>
    <description>once daily tablet</description>
    <arm_group_label>Saxagliptin</arm_group_label>
    <other_name>Onglyza</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        -healthy subjects or patients with type 1 diabetes

        Exclusion Criteria:

          -  pregnancy

          -  treatment with GLP-1-Analoga (Liraglutide, Exenatide)

          -  treatment with DPP4-inhibitor (Sitagliptin, Vildagliptin, Saxagliptin)

          -  chronic disease including a long-term medication over 4 weeks per year (except type 1
             diabetes)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas R Pieber, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Graz</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gerlies Treiber, MD</last_name>
    <phone>+43/316/38512383</phone>
    <email>gerlies.treiber@medunigraz.at</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Silvia Leitgeb, Bcs</last_name>
    <phone>+43/316/38512383</phone>
    <email>silvia.leitgeb@medunigraz.at</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medical University Graz</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Thomas Pieber, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gerlies Treiber, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 3, 2014</lastchanged_date>
  <firstreceived_date>January 30, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>autoimmune disease</keyword>
  <keyword>diabetes type 1</keyword>
  <keyword>incretin effect</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Incretins</mesh_term>
    <mesh_term>Saxagliptin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
